These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33587990)

  • 1. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes.
    Kubeš J; Haas A; Vondráček V; Andrlík M; Navrátil M; Sláviková S; Vítek P; Dědečková K; Prausová J; Ondrová B; Vinakurau Š; Grebenyuk A; Doležal T; Velacková B; Rosina J
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1090-1097. PubMed ID: 33587990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
    Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer-A Retrospective Analysis.
    Kubeš J; Sláviková S; Vítek P; Haas A; Ondrová B; Dedečková K; Andrlík M; Domanský M; Jiránková K; Schlencová V; Harazimová A; Turková B; Doležal T; Al-Hamami SFA; Vondráček V
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.
    Choo R; Hillman DW; Mitchell C; Daniels T; Vargas C; Rwigema JC; Corbin K; Keole S; Vora S; Merrell K; Stish B; Pisansky T; Davis BJ; Amundson A; Wong W
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1085-1094. PubMed ID: 36427645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
    Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionation for clinically localized prostate cancer.
    Hickey BE; James ML; Daly T; Soh FY; Jeffery M
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer.
    Johansson S; Isacsson U; Sandin F; Turesson I
    Radiother Oncol; 2019 Dec; 141():164-173. PubMed ID: 31431382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
    Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
    Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
    Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
    Chen WC; Tokita KM; Ravera J; Fu P; Jiang Y; Kaminsky DA; Ponsky L; Ellis RJ
    Brachytherapy; 2013; 12(5):422-7. PubMed ID: 23380382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
    Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
    J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.